Cargando…

Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study

OBJECTIVES: To assess differences in efficacy of a 28.2-μg teriparatide formulation for twice-weekly use (2/W-TPTD) by patient characteristics. METHODS: A post hoc analysis was performed using data from a multicenter, randomized, double-blind, double-dummy, non-inferiority trial (TWICE study) conduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugimoto, Toshitsugu, Yoshimura, Takeshi, Uzawa, Toyonobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Osteoporosis 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044588/ https://www.ncbi.nlm.nih.gov/pubmed/33869800 http://dx.doi.org/10.1016/j.afos.2020.12.001

Ejemplares similares

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk
por: Ifuku, Emiko, et al.
Publicado: (2019)

Incremental and Once- to Twice-Weekly Hemodialysis: From Experience to Evidence
por: Obi, Yoshitsugu, et al.
Publicado: (2017)

Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis
por: Fujita, Ryo, et al.
Publicado: (2022)

Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice‐Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single‐Blind Randomized Study
por: Kumagai, Yuji, et al.
Publicado: (2019)

Association between elcatonin use and cancer risk in Japan: A follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis
por: Okamoto, Hiroaki, et al.
Publicado: (2020)

Is Twice-weekly Maintenance Hemodialysis Justified?
por: Mendonca, Satish, et al.
Publicado: (2021)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
por: Chiquette, Elaine, et al.
Publicado: (2012)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study
por: OHTA, SHOICHIRO, et al.
Publicado: (2014)

Measure Twice, Cut Once
por: D’Alessandro, David A., et al.
Publicado: (2021)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide
por: Takeuchi, Yasuhiro, et al.
Publicado: (2015)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide
por: Tanaka, Sakae, et al.
Publicado: (2014)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily1
por: Best, J H, et al.
Publicado: (2009)

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers
por: Lam, Edwin, et al.
Publicado: (2020)

Feasibility of Twice-Weekly Hemodialysis During COVID-19
por: Siga, Esteban
Publicado: (2021)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Impact of patient background factors on the treatment efficacy of once-weekly teriparatide
por: Omura, Fumitoshi
Publicado: (2019)

A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis
por: Lee, Joo-Heung, et al.
Publicado: (2016)

A Comparison of Practice Pattern and Outcome of Twice-weekly and Thrice-weekly Hemodialysis Patients
por: Mukherjee, T., et al.
Publicado: (2017)

Once-weekly teriparatide increases bone mineral density in the distal 1/10 radius, but not in the distal 1/3 radius
por: Urushibara, Nobuo, et al.
Publicado: (2014)

Feasibility of Twice-Weekly Hemodialysis: Contingency Planning for COVID-19
por: Clark, David A., et al.
Publicado: (2021)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT
por: Ito, M., et al.
Publicado: (2013)

Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial
por: Javadi, Amir, et al.
Publicado: (2022)

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
por: Sugimoto, T., et al.
Publicado: (2013)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

The social media response to twice-weekly mass asymptomatic testing in England
por: Dennis, Amelia, et al.
Publicado: (2022)

Phosphate Intake and Removal in Predominantly Vegetarian Patients on Twice-Weekly Hemodialysis
por: Rao, Namrata Sarvepalli, et al.
Publicado: (2022)

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
por: Harris, Stewart B., et al.
Publicado: (2017)

Characteristics and perceptions of twice-weekly webinars for primary care physicians in Japan: a qualitative study
por: Kimura, Shinji, et al.
Publicado: (2018)

Comparison of Clinical Outcome Between Twice-Weekly and Thrice-Weekly Hemodialysis in Patients With Residual Kidney Function
por: Hwang, Hyeon Seok, et al.
Publicado: (2016)

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Nonsurgical Corrective Union of Osteoporotic Vertebral Fracture with Once-Weekly Teriparatide
por: Miyakoshi, Naohisa, et al.
Publicado: (2015)

How different is the once-weekly teriparatide from the daily one or the same?
por: Takeuchi, Yasuhiro
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hvh43juarfjc9fdt72c66em4s0